These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 32557093)

  • 41. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
    Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
    Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
    Costa F; Valgimigli M; Steg PG; Bhatt DL; Hohnloser SH; Ten Berg JM; Miede C; Nordaby M; Lip GYH; Oldgren J; Cannon CP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):216-226. PubMed ID: 33258897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
    Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
    Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
    Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
    Choo EH; Choi IJ; Lim S; Moon D; Kim CJ; Park MW; Kim MC; Hwang BH; Lee KY; Seok Choi Y; Kim HY; Yoo KD; Jeon DS; Ahn Y; Chang K;
    Circ Cardiovasc Interv; 2022 Dec; 15(12):e012157. PubMed ID: 36382599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimation of adverse events associated with P2Y12 receptor inhibitors stratified by academic research consortium for high bleeding risk criteria in acute coronary syndrome.
    Fujii T; Endo S; Tsuchiya R; Nagamatsu H; Kasai S; Kawamura Y; Yoshimachi F; Ikari Y
    Int J Cardiol; 2023 Mar; 375():1-6. PubMed ID: 36649890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
    Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
    Kim MC; Ahn SG; Cho KH; Sim DS; Hong YJ; Kim JH; Jeong MH; Lee JW; Youn YJ; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Chang K; Ahn Y
    EuroIntervention; 2023 Dec; 19(10):e832-e843. PubMed ID: 37724337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.
    Ullah W; Sandhyavenu H; Taha A; Narayana Gowda S; Mukhtar M; Reddy Polam A; Zahid S; Fischman DL; Savage MP; Rao SV; Alkhouli M
    J Am Heart Assoc; 2024 Oct; 13(20):e032490. PubMed ID: 39392170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
    Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
    Laine M; Lemesle G; Burtey S; Cayla G; Range G; Quaino G; Canault M; Pankert M; Paganelli F; Puymirat E; Bonello L
    Am Heart J; 2020 Jul; 225():19-26. PubMed ID: 32473355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST-Segment-Elevation Myocardial Infarctions.
    Schmucker J; Fach A; Mata Marin LA; Retzlaff T; Osteresch R; Kollhorst B; Hambrecht R; Pohlabeln H; Wienbergen H
    J Am Heart Assoc; 2019 Sep; 8(18):e012530. PubMed ID: 31538856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention.
    Li Y; Li J; Qiu M; Ma S; Na K; Li X; Qi Z; Chen S; Li Y; Han Y
    Catheter Cardiovasc Interv; 2022 May; 99 Suppl 1():1395-1402. PubMed ID: 35032148
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
    JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
    De Filippo O; Cortese M; D Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Montefusco A; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Rinaldi M
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):381-391. PubMed ID: 31030413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients.
    Sun Y; Li C; Zhang L; Yu T; Ye H; Yu B; Tao M; Jiang J; Yan J; Wang Y; Zeng H; Shen X; Wang DW
    Atherosclerosis; 2019 Nov; 290():52-58. PubMed ID: 31568962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.